At a glance
ClinicalIndex Comparison Record- ✓Histologically or cytologically confirmed cutaneous melanoma with clinical evidence of metastatic disease, unresectable regional lymphatic disease, or extensive in-transit recurrent disease
- ✓Measurable disease: at least 20 mm by conventional imaging or at least 10 mm by spiral CT
- ✓ECOG performance status 0-2 AND Karnofsky score 60-100%
- ✓Life expectancy more than 6 months
- ✕Known brain metastases
- ✕Ocular melanoma
- ✕Symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- ✕Uncontrolled hypertension
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of Bevacizumab and Interferon-Alpha-2b in Metastatic Malignant Melanoma
In Brief
A Phase 2 clinical trial evaluating Recombinant Interferon Alfa and Bevacizumab for Recurrent Melanoma and Stage IV Skin Melanoma. Completed, enrolled 57 participants across 2 sites.
Detailed Summary
This randomized phase II trial is studying giving bevacizumab together with interferon alpha to see how well it works compared to giving bevacizumab alone in treating patients with metastatic malignant melanoma. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Interferon alpha may interfere with the growth of the cancer cells and slow the growth of the tumor. Combining bevacizumab with interferon alpha may kill more tumor cells.
Study Details
Timeline
Interventions
Given SC
Given IV